People · Operator
Named in public records as an officer, director or promoter · active 2008–2025 · Pharmaceuticals, Other, Other Health Care, Biotechnology, Healthtech, Other Technology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Portola Pharmaceuticals Inc | — | Pharmaceuticals | Series C | $158.1M | $315.8M | 2008 |
| Aveo Pharmaceuticals Inc | — | Pharmaceuticals | Series C | $98.2M | $263.2M | 2009 |
| Dfine Inc | — | Other | Series B | $77.3M | $290.6M | 2009 |
| NinePoint Medical, Inc. | — | Other Health Care | Series B | $70.4M | $679.4M | 2009 |
| SentreHEART Inc | — | Biotechnology | Series B | $51.0M | $992.2M | 2012 |
| Chronic Care Management, Inc. | — | Healthtech | Series A | $40.6M | $53.7M | 2021 |
| Baxano, Inc. | — | Other Health Care | Series B | $28.5M | $631.4M | 2010 |
| Third Eye Health, Inc. | — | Healthtech | Series A | $28.4M | $40.8M | 2018 |
| Visiogen Inc | — | Other Health Care | Series B | $20.0M | $443.1M | 2009 |
| datma, Inc. | — | Other Technology | Seed | $2.5M | $10.2M | 2024 |
Russell Hirsch at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Russell Hirsch on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Nicholas Galakatos | 2 | 6 |
| David Clapper | 2 | 6 |
| David Johnson | 1 | 35 |
| Robert Anderson | 1 | 24 |
| Richard Ferrari | 1 | 15 |
| Casey Tansey | 1 | 14 |
| Andrew Firlik | 1 | 14 |
| James Topper | 1 | 12 |
| Jonathan Silverstein | 1 | 10 |
| Paul Buckman | 1 | 10 |
| Mark Levin | 1 | 9 |
| Steven Hochberg | 1 | 9 |
| Richard Lin | 1 | 8 |
| David Johnston | 1 | 8 |
| Jeani Delagardelle | 1 | 8 |
| AMISH PATEL | 1 | 8 |
| Chen Yu | 1 | 7 |
| Csaba Truckai | 1 | 7 |
| Robert Higgins | 1 | 7 |
| Reza Zadno | 1 | 7 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.